论文信息 - Editorial: the microbiome, aspirin and colorectal cancer - 字舞流文

Editorial: the microbiome, aspirin and colorectal cancer

LINKED CONTENTThis article is linked to Prizment et al papers. To view these articles, visit https://doi.org/10.1111/apt.16013 and https://doi.org/10.1111/apt.16115

E. Quigley | J. O'grady

[1] T. Church,et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk , 2020, Alimentary pharmacology & therapeutics.

[2] H. Nielsen,et al. Bifidobacterium breve Bif195 Protects Against Small-intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. , 2019, Gastroenterology.

[3] Y. Zayed,et al. Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials , 2019, Journal of Cancer Research and Clinical Oncology.

[4] Paul J. McMurdie,et al. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer , 2017, Gut.

[5] C. Huttenhower,et al. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial , 2017, Trials.

[6] M. Karin,et al. Targeting Inflammation in Cancer Prevention and Therapy , 2016, Cancer Prevention Research.

[7] W. Willett,et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. , 2016, JAMA oncology.

[8] F. Shanahan,et al. The Gut Microbiota in Causation, Detection, and Treatment of Cancer. , 2019, The American journal of gastroenterology.